• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Imaging and Intervention

Screening mammography may not decrease overall mortality in women ages 40-59

byDavid WangandAndrew Bishara
February 14, 2014
in Imaging and Intervention, Obstetrics, Oncology, Public Health
Reading Time: 3 mins read
Intake of fish fatty acids associated with lower risk of breast cancer
Share on FacebookShare on Twitter

Image: PD

1. A 5 year mammography screening program did not result in a difference in mortality compared to breast examination alone/usual care in women 40-59.

2. 22% of all mammography-detected invasive cancers were considered to be over-diagnoses.

Evidence Rating Level: 2 (Good)

Study Rundown: The use of mammography is a mainstay in breast cancer screening in women >50 years old. However, the exact magnitude of the benefit provided by breast cancer screening has been controversial. The authors of this article presented the results of a 25-year follow-up of a large randomized control trial, which compared 5-year mammography screening to control (breast examination/usual care). Women enrolled were ages 40-59, had no mammograms in the 12 months leading up to the study, had no history of breast cancer, and were not pregnant. In a cohort of over 89,000 participants, the trial demonstrated no difference in 25-year breast cancer specific or all-cause mortality between the mammography and control group. Given this result, the excess number of breast cancer diagnosis made by mammography was considered over-diagnosis of clinically insignificant pathology. Overall, 22% of all screen detected invasive cancers were categorized as over-diagnoses. The results of this study suggests a decreased value of annual mammography screening for women age 50-59 and may lead to diagnosis of cancer which may not be clinically relevant. The strength of this paper is in its high patient compliance as well as the long-term follow-up; however, there are some methodological short-comings that may affect the validity of the trial. In the mammography arm, only 32% of all breast cancer detected was via mammography only. Furthermore, the analysis is based on data from the Canadian National Breast Screening Study, which has been cited by some researchers as flawed for using poor quality mammography machines. In addition, all women received a clinical breast exam before randomization, which may have contaminated the groups so that patients with larger, more palpable tumors were assigned to mammography.

Click to read the study in BMJ

RELATED REPORTS

Daraxonrasib extends survival in metastatic pancreatic cancer

A lower threshold for referral to the emergency department for outpatient hyperkalemia may reduce mortality

Borderline-low hemoglobin levels linked to increased mortality

Click to read an accompanying editorial in BMJ

Relevant Reading: Overdiagnosis in screening mammography in Denmark: population based cohort study

In-Depth [randomized-controlled trial]: This study analyzed results from the Canadian National Breast Screening Study. 89,835 women were followed for incident breast cancer and survival for up to 25 years (mean time of follow-up: 21.9 years). Using a Cox proportional hazards model, there was no statistically significant difference found in the 25 year cumulative mortality from all causes between the mammography and control groups (1.02 95% CI: 0.98-1.06; p=0.28). There was also no statistically significant difference found in breast cancer specific mortality between the two groups (0.99, 95%CI: 0.88-1.12; p=0.87). There was a statistically significant difference in 25 year survival between mammography and control groups, although this was attributed to lead-time and length-time bias. At the end of the 5 year screening, 484 cases of invasive cancer were diagnosed by mammography alone. At 15 years follow-up, there was an excess of 106 diagnoses cases between the mammography and control group. Given similar survival, the authors translated the excess cases to a 22% (106/484) rate of over-diagnosis.

More from this author: First report of acute MERS-CoV infection associated with adverse pregnancy outcome, “Hospital Report Cards” not associated with improved trauma mortality outcomes, Preoperative vitamin D levels may influence post-surgical infection rate, HIV-infected infant potentially cured with antiretroviral therapy, Pediatric appendicitis outcomes in Canada not superior to US

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: Breast Cancercancer screeninghealth policymortalityoncologyover-diagnosispublic healthuspstfwomen ages 40-59
Previous Post

Travel distance to health care associated with advanced colon cancer stage at diagnosis

Next Post

Complement mutation linked to poor response to eculizumab

RelatedReports

Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Emergency

A lower threshold for referral to the emergency department for outpatient hyperkalemia may reduce mortality

September 16, 2026
Cardiology

Borderline-low hemoglobin levels linked to increased mortality

September 14, 2026
Cardiology

Chronic exposure to particulate matter is associated with increased cardiovascular risk

September 10, 2026
Next Post
Complement mutation linked to poor response to eculizumab

Complement mutation linked to poor response to eculizumab

Initial trial of conservative management of splenic injury [Pediatrics Classics Series]

Estimated 1 in 14 women worldwide survivors of sexual violence in lifetime

Estimated 1 in 14 women worldwide survivors of sexual violence in lifetime

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • An ultrasound-guided percutaneous method of vagal nerve stimulation may be effective for refractory chronic pain
  • Daraxonrasib extends survival in metastatic pancreatic cancer
  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.